ArticleNature communications2026
Global incidence of esophageal cancer by histological and anatomical subtypes.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is a major contributor to the global cancer burden, yet comprehensive global assessments of its burden across subtypes are lacking. This study examines the incidence, risk factors, and trends of esophageal cancer by histological and anatomical subtypes, with stratification by sex and age across different countries, using GLOBOCAN 2022 estimates, Cancer Incidence in Five Continents data, and country-level socioeconomic, lifestyle, and metabolic risk-factor indicators. Here we show that Eastern Asia has the highest age-standardized rate (ASR) of incidence of esophageal squamous cell carcinoma (ESCC) (7.2 per 100,000 population) and upper- and middle-third esophageal cancer (6.0), whereas Northern Europe exhibits the highest ASR of incidence of esophageal adenocarcinoma (EAC) (3.2) and lower‑third esophageal cancer (3.6). EAC and lower‑third esophageal cancer generally share risk factors and exhibit increasing trends; in contrast, ESCC and the upper- and middle-third esophageal cancer share a different risk profile and show an overall decreasing trend. In developed regions, EAC and lower‑third esophageal cancer are more common, whereas in developing regions, ESCC and upper- and middle-third esophageal cancer predominate. Our findings may assist the development of tailored prevention strategies based on locally emerging patterns of esophageal cancer subtypes and relevant risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.